298. Hereditary pancreatitis Clinical trials / Disease details
Clinical trials : 98 / Drugs : 180 - (DrugBank : 57) / Drug target genes : 53 - Drug target pathways : 142
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04611958 (ClinicalTrials.gov) | July 1, 2021 | 27/10/2020 | Intraductal Liposomal Bupivacaine for Chronic Pancreatitis | Intraductal Liposomal Bupivacaine as a Therapeutic Trial to Determine the Contribution of Peripheral Versus Central Sensitization in the Pathogenesis of Pain in Chronic Pancreatitis- a Pilot and Feasibility Study | Chronic Pancreatitis | Drug: ERCP with Bupivacaine infusion | Johns Hopkins University | NULL | Withdrawn | 18 Years | 80 Years | All | 0 | Early Phase 1 | United States |